Vera Therapeutics won U.S. accelerated approval for TRUTAKNA (atacicept-vymj) to treat adults with primary IgA nephropathy at risk of disease progression. The FDA decision is based on an interim analysis from the ORIGIN 3 trial, in which TRUTAKNA achieved a 46% reduction in proteinuria from baseline and a statistically significant 42% reduction versus placebo at 36 weeks. The therapy targets immunological drivers by binding both BAFF and APRIL. Vera reported the treatment was generally well tolerated; the most common adverse reactions were infections and local administration reactions. With accelerated approval, Vera positions TRUTAKNA as the first and only available BAFF/APRIL inhibitor for IgAN, setting up competitive dynamics against other pipeline programs in kidney autoimmunity.